Funding News

Mankind Pharma Acquires 70% Stake in Belgian CAR-T Biotech Armed Cell Therapeutics for €48 Million

By Mustafa Shariff, Editor in Chief · October 21,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Mankind Pharma Acquires 70% Stake in Belgian CAR-T Biotech Armed Cell Therapeutics for €48 Million

Summary

  • Mankind Pharma acquires 70% stake in Belgian CAR-T startup Armed Cell Therapeutics for €48M
  • Mankind Pharma has signed a definitive agreement to acquire a 70% controlling stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-incorporated CAR-T cancer therapy company with R&D teams in the US and Europe, for €48 million. The deal is Mankind's first major cell therapy investment.

"This is the first step in building a global pipeline of breakthrough therapies — and making them accessible to patients in India and worldwide."

Mankind Pharma, one of India's largest pharmaceutical companies by revenue (approximately ₹12,000 crore in FY25), announced on October 16, 2026 that it will acquire a 70% majority stake in Armed Cell Therapeutics B.V. (ACTx), a biotech company incorporated in Belgium, for €48 million (approximately ₹511 crore). The transaction was executed through Mankind Pharma (Netherlands) B.V., a subsidiary, and is structured as a definitive agreement — meaning regulatory and board approvals remain pending. The remaining 30% will continue to be held by existing shareholders of ACTx, whose identities have not been publicly disclosed.
What Armed Cell Therapeutics Does
Armed Cell Therapeutics is developing what it describes as "Armed" CAR-T cells — chimeric antigen receptor T-cell therapies that carry additional therapeutic payloads beyond the standard CAR construct. Standard CAR-T therapy involves engineering a patient's own T cells to recognize and attack cancer cells. ACTx's approach adds extra weaponry: its CAR-T cells are designed to carry payloads — such as cytokines or other immune-stimulating molecules — that strengthen and sustain anti-tumor activity once inside the tumor microenvironment, and that can help overcome immune suppression mechanisms that cancer cells commonly deploy to evade T cell killing. The lead programs target non-Hodgkin lymphoma (NHL) and small cell lung cancer (SCLC). The company is also exploring in vivo CAR-T cell generation, a next-generation approach in which CAR-T engineering occurs inside the patient's body rather than in an external manufacturing process — potentially eliminating the expensive and time-consuming ex vivo manufacturing step that limits current CAR-T accessibility. R&D teams are based in the US and Europe.
Why CAR-T? Mankind's Innovation Strategy
Mankind Pharma's COO Arjun Juneja described the deal as "the first step in building a global pipeline of breakthrough therapies." This language reflects a broader strategic pivot underway at Mankind, which built its dominance in India through affordable branded generics — products like Moxikind, Manforce, and AcneStar — but has been under pressure to diversify away from the low-margin generic segment and build innovative, high-value assets. CAR-T therapy sits at the premium end of oncology innovation: currently approved CAR-T products globally (Kymriah, Yescarta, Breyanzi, Carvykti) are priced between $400,000 and $475,000 per treatment in the US. Making cell therapy more accessible in India — where oncology patients face either paying out-of-pocket at these global price points or going without — is the long-term goal Juneja articulated. ACTx's in vivo CAR-T research, if successful, would dramatically reduce manufacturing costs and improve access.
The Indian CAR-T Context
India has been steadily building its own CAR-T capability. IIT Bombay spin-out ImmunoACT received approval from India's CDSCO in October 2023 for NexCAR19, the first indigenously developed, locally manufactured CAR-T therapy, for B-cell lymphomas — priced at approximately ₹23.5 lakh ($28,000), making it among the most affordable CAR-T treatments in the world. Cipla has backed ImmunoACT. Apollo Hospitals has set up a CAR-T cell manufacturing facility. The Indian government's New Drugs and Clinical Trials Rules (2019) provide regulatory pathways for ATMPs (Advanced Therapy Medicinal Products). Mankind's entry into this space through ACTx — a company with US and European R&D teams — adds a global biotech acquisition dimension to what was previously a domestic-focused ecosystem. Mankind gains access to novel payload technology and potential non-Hodgkin lymphoma programs that could be developed for global markets and eventually localised for India.
BHC Perspective: What This Signals for Indian Pharma's Global Ambitions
The Indian pharmaceutical industry has been talking about transitioning from "volumes to value" — from generics to innovation — for more than a decade. The acquisitions of Biocon Biologics assets by Sanofi, Sun Pharma's in-licensing of specialty global products, and now Mankind's €48M bet on a European CAR-T biotech represent different flavors of this transition. What makes the Mankind/ACTx deal distinctive is its choice of cell therapy — the highest-cost, highest-complexity segment of oncology — as the entry point. That is a long bet: CAR-T therapy development timelines run 7–10 years from preclinical to regulatory approval. But for a company of Mankind's scale, €48M is a manageable strategic option on a potentially transformative technology whose eventual access in India will depend on exactly the kind of cost-reducing manufacturing innovation that ACTx is pursuing.
Frequently Asked Questions
Q: What makes "Armed" CAR-T cells different from standard CAR-T therapy?
A: Standard CAR-T therapy engineers a patient's T cells to carry a chimeric antigen receptor (CAR) that recognises a cancer-specific surface protein — such as CD19 in B-cell lymphomas. "Armed" CAR-T cells carry additional therapeutic payloads beyond the standard CAR construct — for example, cytokines, checkpoint inhibitors, or co-stimulatory molecules. These payloads are designed to sustain T cell activity in the tumor microenvironment, where cancer cells often suppress immune responses to escape killing. ACTx's technology also investigates multi-antigen targeting, which makes it harder for cancer cells to escape by downregulating a single surface marker.
Q: What is in vivo CAR-T cell generation, and why does it matter for access?
A: Current approved CAR-T therapies require a complex, expensive ex vivo manufacturing process: a patient's T cells are extracted, shipped to a specialist manufacturing facility, genetically engineered, expanded, quality-checked, shipped back, and re-infused — a process that takes weeks and costs hundreds of thousands of dollars. In vivo CAR-T generation aims to perform the engineering inside the patient's body, using viral vectors or lipid nanoparticles to deliver CAR-encoding genetic material directly to the T cells circulating in the blood. If successful, this would eliminate the manufacturing bottleneck entirely, dramatically reduce cost, and allow treatment in a standard infusion centre rather than a specialist cell therapy unit. ACTx's research in this area is preclinical; regulatory proof-of-concept is likely years away.
Q: Is Mankind Pharma listed? What does this mean for shareholders?
A: Yes — Mankind Pharma (BSE: 543904, NSE: MANKIND) is listed on Indian stock exchanges and is required to disclose material acquisitions under SEBI's LODR (Listing Obligations and Disclosure Requirements) regulations, which is how this deal entered the public record (an NSE filing on October 15, 2026, followed by media coverage on October 16). For shareholders, the €48M investment represents a modest outlay relative to Mankind's balance sheet but a significant strategic statement about the company's long-term innovation ambitions. Analyst reaction will likely focus on the timeline to clinical milestones and whether Mankind will commit additional capital to ACTx's pipeline development.